What are the latest treatment options for PTCL-NOS?

analyse_media

Reading File

Finding Sources

Searching PubMed

peripheral T cell lymphoma IHC diagnosis CD3 CD4 CD8 BCL2

I have sufficient knowledge from the IHC report itself and my training to provide a thorough interpretation. Let me now compile the full expert analysis.

IHC Report Interpretation - Mr. Mohammad Ibrahim Hajam (70M)

Specimen & Context

Specimen: Paraffin block from neck swelling excision (cervical lymph node)
Clinical backdrop: Multiple cervical lymph nodes with loss of fatty hilum at levels II, III, and IV bilaterally
H&E impression: Suspicious for lymphoproliferative neoplasm
IHC performed at: Metropolis Histoxpert (CAP Accredited), reported by Dr. Shaikhal Barodawala, HOD Integrated Oncopathology

IHC Marker-by-Marker Interpretation

Marker	Result	Significance
CD20	Negative	Rules out B-cell lymphoma
PAX5	Negative	Confirms non-B-cell lineage
CD3	Positive	Confirms T-cell lineage
BCL2	Weak and variable	T-cells normally express BCL2; weak/variable is non-specific here
Ki-67	25-30%	Moderate proliferation index - consistent with aggressive T-cell lymphoma
CD15	Negative	Rules out Hodgkin lymphoma (Reed-Sternberg cells are CD15+)
CD30	Variable, highlights immunoblasts	Can be seen in PTCL-NOS and AITL; partial CD30 doesn't mean ALCL
Pan-CK	Negative	Rules out carcinoma metastasis (important in a neck node)
CD5	Positive	Normal T-cell marker retained - suggests a mature/peripheral T-cell neoplasm
S100	Negative	Rules out Langerhans cell histiocytosis and metastatic melanoma/neural tumors
CD4	Positive	Helper T-cell phenotype
CD8	Variable	Mixed or aberrant expression - the "lost" CD7 (below) and variable CD8 suggest aberrant phenotype
CD7	Lost	Key aberrant finding - CD7 loss is a classic marker of neoplastic T-cells; seen in PTCL-NOS and AITL
EBER	Negative	Rules out EBV-driven T-cell lymphoma (nasal NK/T-cell lymphoma, EBV+ DLBCL); also important in excluding AITL where EBV+ B-immunoblasts are common
LCA	Positive	Confirms hematopoietic/lymphoid origin
MUM1	Variable	Plasma cell/activated B-cell marker; variable expression in PTCL is non-specific
BCL6	Variable	Seen in follicular helper T-cells (TFH phenotype) - points toward AITL/TFH lineage
CD10	Negative	AITL typically shows CD10+ neoplastic T-cells; CD10 negativity works against AITL but doesn't exclude it
CD43	Positive	Pan-T/myeloid marker; supports T-cell lineage
OCT2	Negative	B-cell transcription factor absent - confirms non-B-cell

Summary of Findings and Differential Diagnosis

The IHC profile is:

Definitively T-cell lineage (CD3+, CD5+, CD43+, CD4+, LCA+)
Non-B (CD20-, PAX5-, OCT2-)
Non-carcinoma (Pan-CK-)
Non-Hodgkin (CD15-)
Non-EBV-driven NK/T (EBER-)
Aberrant phenotype with CD7 loss - a hallmark of neoplastic T-cells

The pathologist's diagnosis of a T-cell lymphoproliferative disorder is well-supported.

Most likely entities to consider:

Peripheral T-Cell Lymphoma, NOS (PTCL-NOS)

Most common diagnosis when a specific subtype cannot be assigned
CD3+, CD4+ > CD8, CD7 loss common, variable CD30, BCL2+ variable
This profile fits well

Angioimmunoblastic T-Cell Lymphoma (AITL) / Follicular T-cell lymphoma

CD4+ TFH phenotype, BCL6 variable, CD10 usually positive but can be focal/absent
EBER negativity reduces likelihood but doesn't exclude; EBV+ B-immunoblasts may not always be present
CD10 negative works against classic AITL
CD30 variable immunoblasts overlap

ALCL (Anaplastic Large Cell Lymphoma)

Less likely - would expect strong, uniform CD30 positivity (not just variable on immunoblasts)

What the "Variable CD30 on Immunoblasts" Means

This is a subtle but important note. CD30 positivity restricted to immunoblasts (large activated cells) in an otherwise T-cell background can be a reactive-looking feature within a neoplastic T-cell process, or it may indicate scattered large transformed cells. It does NOT indicate ALCL here, as ALCL requires strong diffuse CD30.

Pathologist's Advice and Recommended Next Steps

The report itself recommends:

Correlation with radiology - CT scan of neck/chest/abdomen/pelvis for staging
Complete clinical details - B symptoms (fever, weight loss, night sweats), LDH, CBC
Submission of another enlarged node with proper fixation in 10% neutral buffered formalin for repeat/confirmatory evaluation

Additional workup that should be considered:

Flow cytometry (fresh tissue) - helps define aberrant T-cell phenotype more precisely
T-cell clonality studies (PCR for TCR gene rearrangement) - to confirm clonal T-cell proliferation and distinguish from reactive conditions
FISH/cytogenetics - some PTCL subtypes have characteristic translocations (e.g., DUSP22 in ALCL)
Bone marrow biopsy - for staging
Serum LDH, beta-2 microglobulin - prognostic markers
Hepatitis C serology - associated with some nodal T-cell lymphomas
PET-CT - for metabolic staging

Key Takeaway

This 70-year-old male with bilateral cervical lymphadenopathy at multiple levels has a T-cell lymphoproliferative neoplasm, most consistent with Peripheral T-Cell Lymphoma, NOS (PTCL-NOS) based on:

CD3+, CD5+, CD4+, CD7 loss (aberrant phenotype)
Negative B-cell markers and pan-CK
EBER negative (non-EBV type)
Moderate Ki-67 (25-30%)
Bilateral multilevel nodal involvement

The caveat noted by the pathologist that the node was "suboptimally preserved" is important - a fresh properly-fixed node should be submitted to confirm subtype, as accurate subclassification (PTCL-NOS vs AITL vs other) has significant treatment implications. First-line therapy for most PTCL subtypes is CHOP or CHOP-based regimens, often followed by autologous stem cell transplant in eligible patients, so oncology referral is urgent.